1. Home
  2. ASMB vs OVID Comparison

ASMB vs OVID Comparison

Compare ASMB & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • OVID
  • Stock Information
  • Founded
  • ASMB 2005
  • OVID 2014
  • Country
  • ASMB United States
  • OVID United States
  • Employees
  • ASMB N/A
  • OVID N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • OVID Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASMB Health Care
  • OVID Health Care
  • Exchange
  • ASMB Nasdaq
  • OVID Nasdaq
  • Market Cap
  • ASMB 100.5M
  • OVID 85.2M
  • IPO Year
  • ASMB 2010
  • OVID 2017
  • Fundamental
  • Price
  • ASMB $14.72
  • OVID $1.06
  • Analyst Decision
  • ASMB Buy
  • OVID Strong Buy
  • Analyst Count
  • ASMB 2
  • OVID 5
  • Target Price
  • ASMB $35.00
  • OVID $4.04
  • AVG Volume (30 Days)
  • ASMB 23.4K
  • OVID 248.3K
  • Earning Date
  • ASMB 11-07-2024
  • OVID 11-12-2024
  • Dividend Yield
  • ASMB N/A
  • OVID N/A
  • EPS Growth
  • ASMB N/A
  • OVID N/A
  • EPS
  • ASMB N/A
  • OVID N/A
  • Revenue
  • ASMB $28,326,000.00
  • OVID $631,695.00
  • Revenue This Year
  • ASMB $267.67
  • OVID $21.51
  • Revenue Next Year
  • ASMB $46.15
  • OVID $7,300.79
  • P/E Ratio
  • ASMB N/A
  • OVID N/A
  • Revenue Growth
  • ASMB N/A
  • OVID 113.21
  • 52 Week Low
  • ASMB $8.16
  • OVID $0.68
  • 52 Week High
  • ASMB $19.93
  • OVID $4.10
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 35.66
  • OVID 34.14
  • Support Level
  • ASMB $15.92
  • OVID $0.99
  • Resistance Level
  • ASMB $17.48
  • OVID $1.47
  • Average True Range (ATR)
  • ASMB 1.07
  • OVID 0.11
  • MACD
  • ASMB -0.25
  • OVID -0.03
  • Stochastic Oscillator
  • ASMB 28.54
  • OVID 4.56

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Share on Social Networks: